TXMD

SEC source: 0001209191-23-024386 · doc4.xml · nonDerivative · entry 1

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,853

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-23-012271 · doc4.xml · derivative · entry 1

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023.

F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023.

F1 · derivative.underlying_shares: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023.

SEC source: 0001209191-23-012287 · doc4.xml · derivative · entry 1

Walker Marlan D · CIK 0001820187 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on June 30, 2023.

F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on June 30, 2023.

F1 · derivative.underlying_shares: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on June 30, 2023.

SEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 5

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,853

F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

SEC source: 0001209191-23-005554 · doc4.xml · derivative · entry 8

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,140 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).

F4 · derivative.exercise_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F4 · derivative.expiration_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

SEC source: 0001209191-23-005554 · doc4.xml · derivative · entry 7

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,400 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).

F4 · derivative.exercise_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F4 · derivative.expiration_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

SEC source: 0001209191-23-005554 · doc4.xml · derivative · entry 6

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,400 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).

F4 · derivative.exercise_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F4 · derivative.expiration_date: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

SEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 4

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,902

F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.01 through $5.17, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.

SEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 3

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).

SEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 2

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).

SEC source: 0001209191-23-005554 · doc4.xml · nonDerivative · entry 1

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).

SEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 6

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,610

F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

SEC source: 0001209191-23-004871 · doc4.xml · derivative · entry 10

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,400 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).

F7 · derivative.exercise_date: The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F7 · derivative.expiration_date: The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

SEC source: 0001209191-23-004871 · doc4.xml · derivative · entry 9

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 519 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).

F6 · derivative.exercise_date: Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F6 · derivative.expiration_date: Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

SEC source: 0001209191-23-004871 · doc4.xml · derivative · entry 8

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,066 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).

F5 · derivative.exercise_date: The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F5 · derivative.expiration_date: The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

SEC source: 0001209191-23-004871 · doc4.xml · derivative · entry 7

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 380 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).

F4 · derivative.exercise_date: The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F4 · derivative.expiration_date: The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

SEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 5

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,617

F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.

SEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 4

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,919

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 3

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,519

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 2

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-23-004871 · doc4.xml · nonDerivative · entry 1

Donegan Michael C · CIK 0001627810 · Prin. Fin. and Acctg. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001104659-23-000311 · tm231445-1_4seq1.xml · nonDerivative · entry 1

Rubric Capital Management LP · CIK 0001687509 · 10% owner

Rosen David Efraim · CIK 0001898677 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · ownership.nature: This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001104659-23-024323 · tm237613-1_4aseq1.xml · nonDerivative · entry 1

Rubric Capital Management LP · CIK 0001687509 · Director · 10% owner · See remarks

Rosen David Efraim · CIK 0001898677 · Director · 10% owner · See remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: The Series A Preferred Stock was mandatorily redeemed by the Issuer pursuant to Section 6(b) of the Certificate of Designation, Preferences and Rights of Series A Preferred Stock, establishing the powers designations, preferences and privileges, and the qualifications, limitations or restrictions of the Series A Preferred Stock (the "Series A Preferred Stock COD") at a redemption price of $1,333 per share. A copy of Series A Preferred Stock COD was filed by the Issuer as Exhibit 3.1 of the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 1, 2022.

F2 · ownership.nature: This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001209191-22-060588 · doc4.xml · nonDerivative · entry 3

Bernick Brian · CIK 0001532233 · Co-Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,872

F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations

SEC source: 0001104659-22-126117 · tm2232455-1_4seq1.xml · nonDerivative · entry 1

Rubric Capital Management LP · CIK 0001687509 · 10% owner

Rosen David Efraim · CIK 0001898677 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,757,191

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.98 to $6.15, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001104659-22-125712 · tm2232348-1_4seq1.xml · nonDerivative · entry 2

Rubric Capital Management LP · CIK 0001687509 · 10% owner

Rosen David Efraim · CIK 0001898677 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,742,366

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.80 to $5.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F3 · ownership.nature: This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001209191-23-008817 · doc5.xml · nonDerivative · entry 1

Walker Marlan D · CIK 0001820187 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,969

F1 · kind: This transaction represents a charitable donation.

SEC source: 0001209191-22-060424 · doc4.xml · nonDerivative · entry 1

Naughton Gail K · CIK 0001297506 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.31, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.

SEC source: 0001104659-22-125712 · tm2232348-1_4seq1.xml · nonDerivative · entry 1

Rubric Capital Management LP · CIK 0001687509 · 10% owner

Rosen David Efraim · CIK 0001898677 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,742,066

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.14 to $5.75, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F3 · ownership.nature: This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001209191-22-060588 · doc4.xml · derivative · entry 6

Bernick Brian · CIK 0001532233 · Co-Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,517

Underlying: Common Stock · 3,167 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs).

F6 · derivative.exercise_date: The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022.

F6 · derivative.expiration_date: The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022.

SEC source: 0001209191-22-060588 · doc4.xml · nonDerivative · entry 2

Bernick Brian · CIK 0001532233 · Co-Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,192

F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.

SEC source: 0001209191-22-060588 · doc4.xml · nonDerivative · entry 1

Bernick Brian · CIK 0001532233 · Co-Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-22-060587 · doc4.xml · derivative · entry 7

Walker Marlan D · CIK 0001820187 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 770

Underlying: Common Stock · 388 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs).

F6 · derivative.exercise_date: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.

F6 · derivative.expiration_date: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.

SEC source: 0001209191-22-060587 · doc4.xml · derivative · entry 6

Walker Marlan D · CIK 0001820187 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,311

Underlying: Common Stock · 1,156 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs).

F5 · derivative.exercise_date: The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.

F5 · derivative.expiration_date: The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.

SEC source: 0001209191-22-060587 · doc4.xml · derivative · entry 5

Walker Marlan D · CIK 0001820187 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,010

Underlying: Common Stock · 1,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs).

F4 · derivative.exercise_date: The RSUs vest in three equal installments annually, becoming fully vested on March 30, 2023.

F4 · derivative.expiration_date: The RSUs vest in three equal installments annually, becoming fully vested on March 30, 2023.

SEC source: 0001209191-22-060587 · doc4.xml · nonDerivative · entry 4

Walker Marlan D · CIK 0001820187 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,685

F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.66 through $5.41, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.

SEC source: 0001209191-22-060587 · doc4.xml · nonDerivative · entry 3

Walker Marlan D · CIK 0001820187 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,733

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-22-060587 · doc4.xml · nonDerivative · entry 2

Walker Marlan D · CIK 0001820187 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-22-060587 · doc4.xml · nonDerivative · entry 1

Walker Marlan D · CIK 0001820187 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,189

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-22-060586 · doc4.xml · derivative · entry 3

Glickman Mark A · CIK 0001441461 · Co-Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,466

Underlying: Common Stock · 1,734 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs).

F3 · derivative.exercise_date: The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer.

F3 · derivative.expiration_date: The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer.

SEC source: 0001209191-22-060586 · doc4.xml · nonDerivative · entry 2

Glickman Mark A · CIK 0001441461 · Co-Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,294

F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations

SEC source: 0001209191-22-060586 · doc4.xml · nonDerivative · entry 1

Glickman Mark A · CIK 0001441461 · Co-Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,734

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-22-060585 · doc4.xml · derivative · entry 9

Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 519

Underlying: Common Stock · 262 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).

F7 · derivative.exercise_date: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.

F7 · derivative.expiration_date: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.

SEC source: 0001209191-22-060585 · doc4.xml · derivative · entry 8

Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,066

Underlying: Common Stock · 534 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).

F6 · derivative.exercise_date: The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.

F6 · derivative.expiration_date: The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.

SEC source: 0001209191-22-060585 · doc4.xml · derivative · entry 7

Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 380

Underlying: Common Stock · 380 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).

F5 · derivative.exercise_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.

F5 · derivative.expiration_date: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.

SEC source: 0001209191-22-060585 · doc4.xml · derivative · entry 6

Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).

F4 · derivative.exercise_date: The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022.

F4 · derivative.expiration_date: The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022.

SEC source: 0001209191-22-060585 · doc4.xml · nonDerivative · entry 5

Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,554

F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.76 and $5.29, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.

SEC source: 0001209191-22-060585 · doc4.xml · nonDerivative · entry 4

Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,464

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-22-060585 · doc4.xml · nonDerivative · entry 3

Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,202

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).

SEC source: 0001209191-22-060585 · doc4.xml · nonDerivative · entry 2

Donegan Michael C · CIK 0001627810 · Interim CFO/CAO/VP of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,668

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).